ANIK

Business Context and Reporting Period

Company: Anika Therapeutics, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2002
Business Overview: Anika develops, manufactures, and commercializes therapeutic products based on hyaluronic acid (HA) for bone, cartilage, and soft tissue protection. Key products include ORTHOVISC (osteoarthritis treatment, currently investigational in the U.S.), HYVISC (equine osteoarthritis), and various ophthalmic viscoelastic products (e.g., AMVISC) manufactured for third parties like Bausch & Lomb.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 13.8% to $5.81 million for the six months ended June 30, 2002, compared to $5.10 million in the prior year period. Product revenue rose 13.8% driven by higher ophthalmic sales and HYVISC sales, partially offset by lower ORTHOVISC sales (primarily due to the Turkish market).
• Profitability Improvement: Gross profit increased 49.3% to $1.52 million, with the gross margin expanding from 20.0% to 26.2%. This was attributed to improved manufacturing cost performance and reduced work-in-process inventories.
• Expense Reduction: Selling, general, and administrative (SG&A) expenses decreased 24.0% to $2.47 million, largely due to the absence of $515,000 in separation costs incurred in the first half of 2001 and lower professional fees. Research and development (R&D) expenses decreased 5.7% to $2.14 million due to lower headcount, despite higher costs for the ORTHOVISC clinical trial.
• Net Loss Reduction: Net loss decreased 40.4% to $2.96 million from $4.97 million in the prior year period, primarily due to the elimination of litigation settlement costs ($950,716 in 2001) and reduced operating expenses.
• Cash Flow: Net cash used in operating activities improved to $1.12 million from $2.00 million in the prior year. This was aided by a $940,000 reduction in inventory and a $551,000 increase in deferred revenue.

Guidance, Outlook, Risks, and Unusual Items

• Outlook: Management anticipates cash usage in 2002 will be significantly less than in 2001. They believe current cash and investments ($12.0 million) are sufficient to meet requirements through at least June 30, 2003. No specific revenue guidance was provided, though revenue in 2002 is expected to be consistent with 2001.
• SEC Investigation: The SEC has issued a formal order of investigation regarding historical revenue recognition matters related to ORTHOVISC sales under a prior agreement with Zimmer. The Company is in discussions regarding a potential settlement. The outcome is uncertain, and substantial additional costs could adversely affect financial position.
• Regulatory Risks: ORTHOVISC requires FDA Pre-Market Approval (PMA) for U.S. commercialization. A Phase III clinical trial is ongoing. There is no assurance that the trial will support a PMA filing or that approval will be granted.
• Customer Concentration: The Company is highly dependent on a few customers. For the six months ended June 30, 2002, Bausch & Lomb accounted for 47.1% of product revenue and 46.4% of accounts receivable. Bausch & Lomb's credit rating was downgraded in March 2002, posing a potential liquidity risk.
• Deferred Revenue: Deferred revenue increased significantly to $566,010 (from $15,001 in 2001), largely due to unit pricing provisions under the Bausch & Lomb agreement where prices are subject to retroactive adjustment based on annual volume.

Investor Verification Checklist

• SEC Investigation Status: Verify the current status of the SEC investigation and any potential settlement terms or financial penalties.
• ORTHOVISC Clinical Trial: Monitor the progress and results of the ongoing Phase III clinical trial, as U.S. commercialization depends entirely on FDA approval.
• Bausch & Lomb Relationship: Assess the financial stability of Bausch & Lomb and the terms of the supply agreement, given the Company's heavy reliance (47% of revenue) on this single customer.
• Deferred Revenue Recognition: Review the criteria for recognizing the $566,000 in deferred revenue, specifically regarding the retroactive price adjustments with Bausch & Lomb.
• Liquidity Runway: Confirm that cash burn rates remain consistent with management's projection of sufficiency through mid-2003, especially given the history of operating losses.